Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: Implications for cyclophosphamide metabolism

Drug Metabolism and Disposition

Volumn 30, Issue 5, 2002, Pages 525-530

  Rae, James M ^a,b   Soukhova, Nadia V ^a   Flockhart, David A ^a,c   Desta, Zeruesenay ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORZOXAZONE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DEXTROMETHORPHAN; MEPHENYTOIN; MIDAZOLAM; NORMEPHENYTOIN; PARACETAMOL; PHENACETIN; RECOMBINANT ENZYME; THIOTEPA; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMETHYLATION; DRUG ACTIVATION; DRUG HYDROXYLATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SPECIFICITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, ALKYLATING; ARYL HYDROCARBON HYDROXYLASES; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; ISOENZYMES; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; RECOMBINANT PROTEINS; THIOTEPA;

EID: 0036237885     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.5.525     Document Type: Article

References (34)

1. Cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy
2. A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation
3. Modulation of thiotepa antitumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabolism
4. A biologically active metabolite of cyclophosphamide
5. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes anesthesiology
6. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid potent inhibition of CYP2C19 and CYP3A
7. Development of a comprehensive panel of antibodies against the major xenobiotic metabolizing forms of cytochrome P450 in humans
8. Examination of purported probes of human CYP2B6
9. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450
10. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity
11. Cytochrome P450 2B6 (CYP2B6) metabolizes methadone (M) preferentially and stereospecifically. An explanation of drug interactions with antiretroviral drugs
12. Human CYP2B6: Expression, inducibility and catalytic activities
13. Expression of human cytochrome P450 2B6 in Escherichia coli: Characterization of catalytic activity and expression levels in human liver
14. Metabolism by Taxol and human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme
15. Catalytic role of cytochrome P450 2B6 in the N-demethylation of S-mephenytoin
16. Cyp2b6 and cyp2c 19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes
17. The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene
18. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide
19. Reduction of cyclophosphamide bioactivation by thioTEPA: Critical sequence-dependency in high-dose chemotherapy regimens
20. Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer
21. Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6
22. Role of human CYP2B6 in S-mephobarbital N-demethylation
23. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver
24. Chemistry, pharmacology and pharmacokinetics of N,N′,N″-triethylenethiophosphoramide (thioTEPA)
25. Characterization of cytochrome P-450 2B6 in human liver microsomes
26. Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer
27. Biotransformation of N,N′,N″-triethylenethlophosphoramide: Oxidative desulfurization to yield N,N′N″-triethylenephosphoramide associated with suicide inactivation of a phenobarbital-inducible hepatic P-450 monooxygenase
28. Application of Bradford's protein assay to adrenal gland subcellular fractions
29. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles
30. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin
31. Antitumor Alkylating Agents
32. High-dose chemotherapy regimens for solid tumors
33. Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes
34. Inhibitory monoclonal antibody to human cytochrome P450 2B6